Rituximab and Carmustine, Cytarabine, Etoposide, and Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
This trial is active, not recruiting.
|Treatments||rituximab, carmustine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation|
|Sponsor||University of Nebraska|
|Collaborator||National Cancer Institute (NCI)|
|Start date||May 2002|
|End date||November 2005|
|Trial size||68 participants|
|Trial identifier||NCT00080886, CDR0000357306, UNMC-06302|
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy followed by autologous hematopoietic stem cell transplantation in treating patients who have B-cell non-Hodgkin's lymphoma.
|Intervention model||single group assignment|
evaluation of the relationship between levels of sCD20 in the blood of patients with non-Hodgkin's lymphoma pre and post rituximab/BEAM/autologous peripheral blood progenitor cell transplantation (PBPCT) as they relate to clinical outcomes.
time frame: pre and post transplant
Male or female participants at least 19 years old.
DISEASE CHARACTERISTICS: - Diagnosis of non-Hodgkin's lymphoma - Any B cell - CD20-positive disease - Failed prior primary induction therapy - Meets 1 of the following criteria: - Chemotherapy-refractory disease - Received at least 3 prior chemotherapy regimens - Mantle cell lymphoma - Eligible for transplantation - No history of T-cell lymphoma PATIENT CHARACTERISTICS: Age - 19 and over Performance status - WHO 0-2 Life expectancy - At least 6 months Hematopoietic - Absolute neutrophil count ≥ 1,000/mm^3* - Platelet count > 50,000/mm^3* - Hemoglobin > 9.0 g/dL* NOTE: *Unless due to lymphomatous involvement of the bone marrow Hepatic - Not specified Renal - Not specified Other - Not pregnant or nursing - Fertile patients must use 2 methods of effective contraception - No other concurrent serious disease or condition that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified
|Official title||A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma|
|Principal investigator||Robert G Bociek, MD|
|Description||OBJECTIVES: - Determine the levels of soluble CD20 antigen (sCD20) in the blood before and after treatment with rituximab and carmustine, cytarabine, etoposide, and melphalan followed by autologous hematopoietic stem cell transplantation in patients with CD20-positive B-cell non-Hodgkin's lymphoma. - Correlate the effect of changes in levels of sCD20 with clinical outcomes in patients treated with this regimen. - Determine the response rate in patients treated with this regimen. - Determine the event-free survival of patients treated with this regimen. - Determine the toxicity profile of this regimen in these patients. OUTLINE: Patients receive rituximab IV over approximately 3-4 hours once weekly for 2 weeks followed 1 week later by hematopoietic stem cell or bone marrow harvest. Patients then receive a third dose of rituximab IV over approximately 3-4 hours on day -7 or -6. Patients also receive high-dose chemotherapy comprising carmustine IV on day -6, cytarabine IV and etoposide IV twice daily on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplantation on day 0. Patients who have less than a complete remission at day 100 post-transplantation receive 4 additional doses of rituximab IV over approximately 3-4 hours once weekly for 4 weeks. Patients are followed at day 100, at 1 year, and then annually thereafter. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.|
Call for more information